Today I talk with Dr. Michael Hughes, he is a consultant rheumatologist at Salford Royal Hospital, which is a national UK referral center for SSc, and Honorary Senior Clinical Lecturer at The University of Manchester. He has emerged as a leading national and international investigator in SSc and Raynaud’s phenomenon, with a focus on novel clinical assessment of vascular biology and function, including the development of new novel approaches to treatment. His doctoral PhD research fellowship (2013-2016) at The University of Manchester investigated the outcome measures of treatment efficacy, pathophysiology, and local treatments for SSc-digital ulcers. Dr.Hughes has a strong research interest in non-invasive imaging and the development of patient reported outcome measures, and works closely with patient-led organizations. He was awarded the Edith Busch Young Investigator Award in recognition of his significant contributions during the World Scleroderma Congress in 2022. Under the auspices of the World Scleroderma Foundation he leads the Digital Ulcer Working Group, and co-leads the Gastrointestinal disease Working Group. Dr. Hughes has published extensively in both clinical and basic research and has contributed to the development of SSc treatment guidelines and recommendations. He contributes to many international initiatives and collaborations including as a Fellow of the OMERACT Scleroderma Vascular Disease Working Group. He has presented and chaired (including invited oral presentations) at prestigious national and international conferences and is on the editorial board of several international rheumatology journals. Furthermore, he has published several studies in high-impact journals as lead author utilizing data from the EUSTAR cohort. Our topic today is 3 things that affect me. Raynauds, calcinosis, and digital ulcers. Lots of great information and helpful hints!